Enquirer Consulting Group

Reachable Buyer Map

Prepared for Cristina Valle Bosch · ESTEVE · August 2026
Two businesses under one name, selling into two different rooms. The contract manufacturing side sells capacity and chemistry to people who already have a molecule. The specialty pharma side acquires and licenses products rather than selling them. This map covers where the buying roles sit in the first, and names where the second one's counterparties are. It describes the market rather than your business, and there is nothing to buy at the end of it.
European specialty and generic pharmaceutical companies
The nearest market to a contract manufacturing business and the one with the shortest distance between a first conversation and a technical package. Big enough to run several external programs at once, small enough that one person owns the decision.
Who signs: head of external manufacturing, VP of supply chain, CMC lead, and the API sourcing manager.
1,800 to 2,400
European pharmaceutical manufacturers carrying 50 or more people; the wider count including micro companies is several times larger
United States specialty and generic pharmaceutical companies
The market where a European supplier is judged first on whether it is genuinely present in the country and second on everything else. A site on the ground changes that conversation, but only for the companies that know it exists.
Who signs: VP of external manufacturing, head of API sourcing, head of technical operations, and the procurement lead on multi-year supply.
1,000 to 1,400
United States headquartered pharmaceutical companies operating registered drug establishments at commercial scale
Clinical-stage small molecule developers
The highest volume of first conversations and the longest odds on any one of them. What makes the segment worth working is that the supplier chosen for the clinical batches usually keeps the molecule, so an early yes is a decade-long position.
Who signs: head of CMC, VP of technical operations, chief scientific officer, and at the smallest companies the founder.
1,200 to 1,800
companies in Europe and the United States with an active small molecule program; not registered anywhere as a group, so identified from published trial and financing disclosures
Animal health and veterinary pharmaceutical companies
A quiet segment that runs on the same chemistry and the same quality standards, buys with fewer people in the room, and is worked by almost nobody selling into human pharma. Smaller volumes, faster decisions.
Who signs: head of manufacturing, technical director, and the sourcing lead.
300 to 500
European veterinary and animal health manufacturers of meaningful scale
Licensing and portfolio counterparties
The other half of the company buys rather than sells. The counterparty is a company holding a product with no commercial route into the markets you already cover, and it is the one group here that no list can be bought for.
Who signs: VP of business development, head of licensing, regional general manager, and the chief executive at smaller companies.
No public register
licensing intent is never filed anywhere; this group is identified company by company from published portfolio, approval and trial disclosures

Where the openings are

1
Selling capacity and buying products are opposite reach problems. One needs to be found by technical people who already have a molecule. The other needs to find companies before they run a formal partnering process. They are usually treated as one function and staffed as neither.
2
The sourcing seat changes rarely and remembers early. Requalifying a supplier is expensive enough that nobody does it casually, so the reachable moment is a supply event: a second source mandate, an incumbent problem, a site closure, a volume step up. Those signals are visible from outside if something is watching the whole market weekly.
3
The United States is a list problem before it is a sales problem. A thousand to fourteen hundred named companies, a handful of roles inside each, and a European supplier's biggest disadvantage there is simply not being in the room when the shortlist gets written. That is fixable mechanically and it does not need more people on the ground first.
4
Clinical-stage developers are underworked because they are hard to count. They do not sit in any register as a group, which means anyone buying a list reaches the wrong companies. Building that audience takes identification rather than purchase, and that difficulty is precisely why the segment stays open.
Built from public market data covering licensed pharmaceutical manufacturers, registered establishments and published clinical and financing disclosures, current to the most recent published year. Counts are banded deliberately. Company size bands use reported employment, so they indicate scale rather than an exact headcount. Two of the segments above are not enumerated as a group in any public source and are identified one company at a time rather than counted.
ENQUIRER CONSULTING GROUP
enquirerconsulting.com